<DOC>
	<DOCNO>NCT01556477</DOCNO>
	<brief_summary>The propose phase II trial multicenter , randomize , open-label study evaluate efficacy safety azacitidine alone combination lenalidomide high-risk Myelodysplastic Syndrome ( MDS ) Acute Myeloid Leukemia ( AML ) karyotype include del ( 5q ) . The primary objective evaluate efficacy term response accord International Working Group ( IWG ) criteria MDS AML 6 cycle azacitidine azacitidine + lenalidomide treatment , end study occur early time point .</brief_summary>
	<brief_title>The Efficacy Azacitidine +/- Lenalidomide High-risk Myelodysplastic Syndrome ( MDS ) Acute Myeloid Leukemia ( AML ) With Del ( 5q ) .</brief_title>
	<detailed_description>This prospective open multi-center randomize phase II study standard dose azacytidine without addition lenalidomide high-risk myeloid disease ( high-risk MDS AML ) karyotype include del ( 5q ) . Seventy-two patient , eligible treatment azacytidine ( Intermedium/INT-2 High-risk MDS AML 20-30 % marrow blast accord label ) include . Azacytidine give modify standard dose , azacytidine 5+2 ( 75 mg/m2/ subcutaneously 5 day , follow 2-day weekend break , follow azacytidine 75 mg/m2/ 2 day every 28 day , individual dose exceed 200 mg ) 6 cycle . Cycle interval may prolong toxicity accord predefined criterion occurs . Patients randomized azacytidine ( Arm A ) azacytidine + lenalidomide ( Arm B ) . The initial dose lenalidomide 10 mg 21/28 day , start day 1 azacytidine cycle leave last week start next azacytidine cycle free . The dose increase 20 mg day 1 cycle 4 toxicity accord predefined criterion occurs . The total study period 24 week + additional week cause prolonged cycle interval . Patients , follow response may eligible allo-SCT may exit study cycle 3 , 4 5 subject end-of-study assessment . Patients start treatment , time study neutrophil count &lt; 0,5 x 109/l treat Granulocyte-ColonyStimulatingFactor ( G-CSF ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>18 year age time sign informed consent form . MDS IPSS Int2 High karyotype include del ( 5q ) . Acute myeloid leukaemia ( AML ) multilineage dysplasia 2030 % blast ( former RAEBt ) karyotype include del ( 5q ) . Subject sign informed consent form . Women childbearing potential ( WCBP ) must negative serum urine pregnancy test prior start lenalidomide . In addition , sexually active WCBP must agree use adequate contraceptive method ( oral , injectable , patch , implantable hormonal contraceptive method ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner ) lenalidomide . WCBP must agree pregnancy test every 4 week lenalidomide . Males ( include vasectomy ) must use barrier contraception ( latex condom ) engage reproductive sexual activity WCBP lenalidomide , temporarily stop lenalidomide 28 day last dose lenalidomide . Note : Refractory relapse patient include long fulfil inclusion criterion . Eligible upfront allogeneic SCT without prior induction chemotherapy azacitidine Pregnant lactating female . Prior therapy azacitidine Prior therapy lenalidomide Expected survival less two month . Acute promyelocytic leukemia ( APL ) Central nervous system leukemia Serum biochemical value follow 1 . Serum creatinine &gt; 2.0 mg/dL ( 177 mmol/L ) 2 . Serum aminotransferase ( AST ) /serum glutamicoxaloacetic transaminase ( SGOT ) alanine transferase ( ALT ) /serum glutamate pyruvate transaminase ( SGPT ) &gt; 3.0 x upper limit normal ( ULN ) 3 . Serum total bilirubin &gt; 1.5 mg/dL Prior allergic reaction thalidomide Uncontrolled systemic infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>MDS</keyword>
	<keyword>AML</keyword>
	<keyword>Azacitidine</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>del5q</keyword>
</DOC>